关键词: 丙型肝炎, 丙型肝炎病毒基因1b型, 达拉他韦, 阿舒瑞韦, 治疗

Abstract: Objective The aim of this study was to investigate efficacy of dacatevir (DCV) and asurevir (ASV) combination in the treatment of patients with chronic hepatitis C (CHC) with hepatitis C virus (HCV) genotype 1b infection. Methods 56 patients with CHC with HCV genotype 1b infection were recruited in our hospital between January 2020 and January 2023, and 55 patients but 1 patient dropped out received dacatavir plus asulivir combination treatment for 12 weeks, and all were followed-up for 24 weeks. Serum HCV RNA loads were determined by RT-PCR, and aspartate aminotransferase/platelet ratio (APRI) was routinely calculated. Results At baseline, serum HCV RNA load in the 55 patients with CHC was (6.0±0.6)lg IU/mL, and it transferred to (4.3±0.5)lg IU/mL, (＜1.7)lg IU/mL and (＜1.7)lg IU/mL 4 weeks and 12 weeks during antiviral therapy and 24 weeks of follow-up, with complete virological response(CVR) of 20.0%, 100.0% and 100.0%, respectively; serum AST, ALT levels and APRI were (74.5±24.5)U/L, (83.0±9.6)U/L and (4.3±1.7), and all returned to normal at end of antiviral regimen and at end of 24 week of follow-up; peripheral white blood cell count, neutrophils count and platelet count elevated to normal(P＜0.05), and blood hemoglobin level didn’t change (P＞0.05)at end of 24 week of follow-up. Conclusion Combination of DCV and ASV antiviral therapy have a good short-term efficacy in the treatment of patients with CHC with hepatitis C virus genotype 1b infection, and long-term efficacy needs further observation.

Key words: Hepatitis C, Hepatitis C viral genotype 1b, Dalatavir, Asurivir, Therapy